surrozen is a biotechnology company focused on discovering and developing novel regenerative medicines with a focus on unlocking the powerful self-renewal properties of the body through specific control of the wnt signaling pathway. surrozen is founded by four leading edge scientists from stanford university: k. christopher garcia, ph.d.; roel nusse, ph.d.; calvin kuo, m.d., ph.d.; and claudia janda, ph.d. each has conducted extensive research on wnt signaling, with findings that together shape surrozen’s technology and approach to therapeutic development. the company is backed by the column group, a leading biotechnology venture capital firm. we are currently seeking highly creative scientists to join our founding team, and invite you to explore career opportunities on our website. if you don’t find a perfect job match, but think surrozen may be the right place for you, please submit your resume to careers@surrozen.com.
Company profile
Ticker
SRZN, SRZNW
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Consonance-HFW Acquisition Corp.
SEC CIK
Corporate docs
Subsidiaries
Surrozen Operating, Inc. • Surrozen Netherlands, B.V. ...
IRS number
981556622
SRZN stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
10 Apr 24
10-K
2023 FY
Annual report
10 Apr 24
8-K
Entry into a Material Definitive Agreement
2 Apr 24
NT 10-K
Notice of late annual filing
2 Apr 24
8-K
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043
1 Apr 24
424B3
Prospectus supplement
7 Feb 24
8-K
Departure of Directors or Certain Officers
7 Feb 24
424B3
Prospectus supplement
22 Jan 24
8-K
Other Events
18 Jan 24
424B3
Prospectus supplement
13 Dec 23
Transcripts
Latest ownership filings
SC 13G
RA CAPITAL MANAGEMENT, L.P.
15 Apr 24
SC 13D/A
COLUMN GROUP III GP, LP
8 Apr 24
4
Charles O Williams
8 Apr 24
4
Craig C Parker
8 Apr 24
4
Tim Kutzkey
8 Apr 24
4
Change in insider ownership
8 Apr 24
SC 13G
Alyeska Investment Group, L.P.
14 Feb 24
SC 13G
GOLDMAN SACHS GROUP INC
9 Feb 24
4
Craig C Parker
7 Feb 24
SC 13G/A
BML Investment Partners, L.P.
7 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 34.40 mm | 34.40 mm | 34.40 mm | 34.40 mm | 34.40 mm | 34.40 mm |
Cash burn (monthly) | 833.33 k | (no burn) | 3.73 mm | 3.19 mm | 3.38 mm | 2.77 mm |
Cash used (since last report) | 5.51 mm | n/a | 24.64 mm | 21.04 mm | 22.31 mm | 18.31 mm |
Cash remaining | 28.90 mm | n/a | 9.76 mm | 13.36 mm | 12.09 mm | 16.09 mm |
Runway (months of cash) | 34.7 | n/a | 2.6 | 4.2 | 3.6 | 5.8 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 44 |
Opened positions | 24 |
Closed positions | 0 |
Increased positions | 3 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 7.60 bn |
Total shares | 30.75 mm |
Total puts | 0.00 |
Total calls | 73.90 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Column Group Iii GP | 9.41 mm | $0.00 |
Column | 9.41 mm | $4.61 bn |
BML Investment Partners | 1.67 mm | $988.00 k |
Euclidean Capital | 1.49 mm | $651.60 mm |
BLK Blackrock | 1.07 mm | $523.60 mm |
Baker Bros. Advisors | 833.33 k | $34.25 mm |
Harvard Management | 826.85 k | $405.00 k |
Board of Trustees of The Leland Stanford Junior University | 781.96 k | $383.16 mm |
Trustees of Columbia University in the City of New York | 752.28 k | $353.65 mm |
LMR Partners | 648.29 k | $26.65 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
4 Apr 24 | Tim Kutzkey | Common Stock | Buy | Acquire P | Yes | No | 15.5 | 102,651 | 1.59 mm | 332,885 |
4 Apr 24 | Tim Kutzkey | Common Stock | Buy | Acquire P | Yes | No | 15.5 | 90,897 | 1.41 mm | 294,767 |
4 Apr 24 | Tim Kutzkey | Series D Common Warrants Common Stock | Buy | Acquire P | Yes | No | 16 | 397,773 | 6.36 mm | 397,773 |
4 Apr 24 | Tim Kutzkey | Series D Common Warrants Common Stock | Buy | Acquire P | Yes | No | 16 | 352,225 | 5.64 mm | 352,225 |
4 Apr 24 | Tim Kutzkey | Series C Common Warrants Common Stock | Buy | Acquire P | Yes | No | 16 | 397,773 | 6.36 mm | 397,773 |
4 Apr 24 | Tim Kutzkey | Series C Common Warrants Common Stock | Buy | Acquire P | Yes | No | 16 | 352,225 | 5.64 mm | 352,225 |
4 Apr 24 | Tim Kutzkey | Series B Common Warrants Common Stock | Buy | Acquire P | Yes | No | 14.25 | 111,656 | 1.59 mm | 111,656 |
4 Apr 24 | Tim Kutzkey | Series B Common Warrants Common Stock | Buy | Acquire P | Yes | No | 14.25 | 98,870 | 1.41 mm | 98,870 |
4 Apr 24 | Tim Kutzkey | Series A Common Warrants Common Stock | Buy | Acquire P | Yes | No | 15.5 | 102,651 | 1.59 mm | 102,651 |
4 Apr 24 | Tim Kutzkey | Series A Common Warrants Common Stock | Buy | Acquire P | Yes | No | 15.5 | 90,897 | 1.41 mm | 90,897 |